Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia

AIMS: The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to investigate the pharmacokinetics and safety of subcutaneous (s.c.) rituximab compared with intravenous (i.v.) rituximab, both in combination with fludarabine and cyclophosphamide (FC), as first line treatment for pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Assouline, Sarit, Buccheri, Valeria, Delmer, Alain, Gaidano, Gianluca, McIntyre, Christine, Brewster, Michael, Catalani, Olivier, Hourcade-Potelleret, Florence, Sayyed, Pakeeza, Badoux, Xavier
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2015
Assuntos:
Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631173/
https://ncbi.nlm.nih.gov/pubmed/25900065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12662
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados